Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-07-25 | Reverse | 1:20 |
OncoCyte Corporation, founded in 2009 in Irvine, CA, develops and commercializes proprietary molecular tests for cancer detection, including DetermaRx and DetermaIO, and collaborates with Life Technologies on advanced genomic assays.

GraftAssureCore is a CLIA-certified blood test that measures donor-derived cell-free DNA to monitor solid organ transplant rejection, with Medicare reimbursement and a target market of approximately $1 billion.
| Icon | PRODUCT | Q1-2025 | Q2-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|---|
![]() | Pharma Services | $2.14M | — | — | — |
![]() | Laboratory Services | — | $494K | $3.54M ▲ | $32K ▼ |
| Map | REGION | Q1-2025 | Q2-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $2.14M | $494K ▼ | $1.4M ▲ | $32K ▼ |
![]() | Europe | — | $24K | $0 ▼ | — |
Overall rating: C
| PEER | PRICE | |
|---|---|---|
OABI | $4.47 | COMPARE |
PRLD | $5.47 | COMPARE |
CCCC | $3.85 | COMPARE |
IVVD | $0.96 | COMPARE |
PEPG | $3.08 | COMPARE |
CDXS | $1.59 | COMPARE |
MIST | $1.16 | COMPARE |